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ABSTRACT
Objectives: To describe the development process for
defining an appropriate model structure for the
economic evaluation of test–treatment strategies for
patients with monogenic diabetes (caused by
mutations in the GCK, HNF1A or HNF4A genes).
Design: Experts were consulted to identify and define
realistic test–treatment strategies and care pathways.
A systematic assessment of published diabetes models
was undertaken to inform the model structure.
Setting: National Health Service in England and Wales.
Participants: Experts in monogenic diabetes whose
collective expertise spans the length of the patient care
pathway.
Primary and secondary outcomes: A defined model
structure, including the test–treatment strategies, and
the selection of a published diabetes model appropriate
for the economic evaluation of strategies to identify
patients with monogenic diabetes.
Results: Five monogenic diabetes test–treatment
strategies were defined: no testing of any kind, referral
for genetic testing based on clinical features as noted by
clinicians, referral for genetic testing based on the
results of a clinical prediction model, referral for genetic
testing based on the results of biochemical and
immunological tests, referral for genetic testing for all
patients with a diagnosis of diabetes under the age of
30 years. The systematic assessment of diabetes
models identified the IMS CORE Diabetes Model (IMS
CDM) as a good candidate for modelling the long-term
outcomes and costs of the test–treatment strategies for
monogenic diabetes. The short-term test–treatment
events will be modelled using a decision tree which will
feed into the IMS CDM.
Conclusions: Defining a model structure for any
economic evaluation requires decisions to be made.
Expert consultation and the explicit use of critical
appraisal can inform these decisions. Although arbitrary
choices have still been made, decision modelling allows
investigation into such choices and the impact of
assumptions that have to be made due to a lack of data.
INTRODUCTION
Monogenic diabetes, caused by mutations in
the GCK, HNF1A or HNF4A genes, differs to
known type 1 and type 2 diabetes in terms of
disease progression and the treatments
patient receive. Rather than the more inva-
sive and expensive treatment of subcutane-
ous insulin, patients with HNF1A and
HNF4A mutations can be successfully treated
with sulfonylureas, while patients with GCK
mutation rarely require pharmacological
treatment.1–5 The challenge is to diagnose
monogenic diabetes, as many patients with
monogenic diabetes will be mislabelled as
having type 1 or type 2 diabetes and will con-
tinue to inject insulin.
Diabetes has a substantial clinical impact
on the patient’s health and well-being, in
addition to being a large economic burden
for healthcare systems. It is estimated that
most people with monogenic diabetes are
initially inappropriately managed due to mis-
diagnosis.6 7 Identifying patients with mono-
genic diabetes and selecting the appropriate
treatment option should lead to reduced
treatment costs and improved health status
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for patients. Genetic testing for monogenic diabetes is
available via the National Health Service in England and
Wales (NHS) and costs £350 per test.8 However, evi-
dence indicates varied patterns of referral rates for
genetic testing for monogenic diabetes across geograph-
ical regions in the NHS.9 Approaches to improve the
identiﬁcation of patients eligible for genetic testing of
monogenic diabetes exist: improving the awareness and
understanding of monogenic diabetes in healthcare pro-
fessionals,10 the development of statistical clinical predic-
tion models,11 and the use of two phenotype-based tests
to (1) measure biochemical levels using the urinary
C-peptide creatine ratio (UCPCR)12 and (2) identifying
the presence of pancreatic autoantibodies.13 Using such
approaches alongside genetic testing and followed by
appropriate treatment selection (oral sulfonylurea or a
controlled diet) has the potential to inform the effective,
safe and cost-effective management of people with
monogenic diabetes. To date, there has been no robust
evaluation to assess the most cost-effective approaches to
identify patients with monogenic diabetes.
Modelling test–treatment strategies has many chal-
lenges. These include a greater number of strategies to
be considered due to different sequences or combina-
tions of tests,14 and the greater complexity of such
models to reﬂect not only the initial testing aspects, but
also any follow-up testing, treatment and monitoring of
patients.14 Thus, it is important to accurately reﬂect the
test–treatment strategies and associated care pathways
when building a model.15 Each structural choice involves
a consideration of the inclusion of speciﬁc parameters,
the deﬁnition of those parameters, how they relate to
other parameters in the model and the availability of
research or other evidence to inform them.16 As the
model structure impacts on all parts of the study,16 17
even on the results of the cost-effectiveness modelling,18
it is essential that the structure is informed, defensible
and explicit.16 19 20 The aim of this study is to describe
the development process for deﬁning an appropriate
model structure for test–treatment strategies for mono-
genic diabetes. There were two speciﬁc objectives: (1) to
identify the number of possible test and treatment strat-
egies that are potentially feasible to target the treatment
of people with monogenic diabetes and (2) to select an
appropriate model type and structure to represent the
identiﬁed test–treatment strategies and subsequent
impact on care pathways.
This economic evaluation forms a part of a larger
project: Using genetics to Improve Treatment of
Early-onset Diabetes—the UNITED study (see http://
www.hicfund.org.uk/HICFundPortfolio/Theme1.aspx).
The main aims of the UNITED study are (1) to estimate
the prevalence of monogenic diabetes in the UK and
(2) to provide evidence for a systematic care pathway for
the diagnosis and treatment of patients with monogenic
diabetes.
In the Methods section, the methods used to identify
and deﬁne realistic test–treatment strategies and the
selection of a long-term diabetes model are described.
In the Results section, the deﬁned test–treatment strat-
egies and model structure (including assumptions and
likely data sources) are given in detail. Challenges and
limitations in the development of an economic evalu-
ation of test–treatment strategies in monogenic diabetes
are discussed, followed by brief conclusions.
METHODS
Defining test–treatment strategies and care pathways
The identiﬁcation and deﬁnition of care pathways was
undertaken iteratively through discussion with a number
of experts. A meeting was held with the consultant phys-
ician, the diabetes nurse and the project coordinator for
the UNITED study. During this initial meeting, discussion
centred on the test–treatment strategies that were feasible
for patients with monogenic diabetes, and the care path-
ways associated with these strategies. Once possible test–
treatment strategies were agreed upon, further develop-
ment on the speciﬁcs of the strategies and the care path-
ways was undertaken through email, telephone and
one-to-one meetings with individual members of the
UNITED clinical team (in particular, the diabetes nurse,
project coordinator and the clinical scientists) where
necessary. When these were further deﬁned, they were
presented at a meeting with members of the UNITED
clinical team (including diabetes nurses, clinical molecu-
lar geneticists and clinical scientists) and the UNITED
study Steering Group for discussion. The UNITED study
Steering Group consists of 12 members, including repre-
sentatives from the UNITED study funding bodies,
experts in diabetes, statistics and economic evaluation.
The collective expertise of the Steering Group and the
UNITED study clinical team spans the length of the care
pathway. Further detailing and amendments to the pro-
posed test–treatment strategies were made as a result of
these discussions.
Defining model structure
A systematic assessment of diabetes models available in
the published literature was undertaken to help inform
the type and structure of the decision model to be used.
The diabetes models that were assessed were those evalu-
ated in two recent reviews of diabetes models by Yi
et al21 and Tarride et al.22 Criteria for diabetes models
from the American Diabetes Association (ADA)23 and
criteria speciﬁc to the needs of this economic evaluation
were used to assess the established models. These cri-
teria included demonstrated internal and external valid-
ity, a long-term time horizon, interdependence between
modelled complications, capture of glycated haemoglo-
bin, analysis of quality-adjusted life-years (QALYs) and
previous use in the published literature and in health
technology assessment (HTA) submissions to reimburse-
ment organisations. Taking information from the
descriptive articles for these models and information
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reported in Yi et al and Tarride et al, the assessment cri-
teria were applied to each diabetes model.
RESULTS
Test–treatment strategies and care pathways
Based on discussions with experts, ﬁve strategies were
deﬁned to represent realistic options within the NHS,
and are summarised in table 1.
Strategy 1 is the most basic strategy where no patients
are referred for genetic testing, and therefore no treat-
ment change is modelled for any patient. This strategy
represents the current situation as seen by the National
Institute for Health and Clinical Excellence (NICE),
since there is no NICE guidance speciﬁcally for mono-
genic diabetes as distinct from type 1 or type 2 diabetes.
Strategy 2 is intended to represent the observed
current practice in the UK where some patients are
referred for genetic testing based on their clinical fea-
tures as noted by clinicians. Currently, referral for
genetic testing is dependent on the knowledge and
awareness of clinicians or diabetes nurses. Data from
Shields et al9 demonstrate great variation in referral and
diagnosis rates between different regions of the UK with
the South West of England having the highest referral
rate (105.9 per million regional population leading to a
total of 28.4 cases per million) and Wales having the
lowest referral rate (13.1 per million of the regional
population leading to 12.4 cases per million).
Strategy 3 is modelled as a potential improvement on
current practice (strategy 2), where referral for genetic
testing is more systematic; yet it is still based on the clin-
ical features of the patient. A clinical prediction model
has been developed for identifying patients likely to
have monogenic diabetes11 and is available online
(http://www.diabetesgenes.org/content/
mody-probability-calculator).
Strategy 4 represents a systematic pathway consisting of
biochemical (UCPCR) and immunological (pancreatic
autoantibody) testing. While patients with monogenic
diabetes continue to produce their own insulin, type 1
diabetes is characterised by insulin deﬁciency. C-peptide
testing in blood has been identiﬁed as a marker of those
patients producing their own insulin,24 and recent work
has demonstrated that UCPCR is a good discriminator
between type 1 patients and those with HNF1A, HNF4A
or GCK mutations.12 25 However, patients newly diag-
nosed with type 1 diabetes are considered to be in a
‘honeymoon’ phase, where they continue to produce
insulin of their own, up to 5 years post-diagnosis, and
therefore will be UCPCR test positive.26 For strategy 4 to
be effective, a test to help distinguish between honey-
mooning type 1 patients and those with HNF1A, HNF4A
or GCK mutations is needed. McDonald et al13 have
identiﬁed pancreatic autoantibody testing for this
purpose. The presence of these antibodies characterises
type 1 diabetes, but their prevalence in cohorts of
patients with monogenic diabetes is similar to the
general population.13 Tests for two particular antibodies
have been proposed and evaluated by McDonald et al:
glutamate decarboxylase (GAD) and islet antigen-2
(IA-2). Strategy 4 is therefore deﬁned by patients cur-
rently on insulin treatment being offered the UCPCR
test. Those testing positive or not currently on insulin
treatment (therefore producing their own insulin) will
be offered the GAD and IA-2 tests. Patients testing
Table 1 Test–treatment strategies for patients’ diagnosed with diabetes when <30 years
Strategy Definition Treatment implications Policy implications
1. No testing No clinical, biochemical,
immunological or genetic testing
No treatment change offered.
Patients with monogenic
diabetes continue on treatment
as from initial diagnosis
The situation as currently seen by
NICE
2. Current practice Patients referred for genetic
testing on basis of clinical features
as noted by clinicians
Treatment change offered Current practice likely to evolve
over time with increasing
awareness of monogenic
diabetes. Costs associated with
this strategy are also likely to
change over time
3. Prediction model Patients referred for genetic
testing on basis of prediction
model
Treatment change offered Information included in the
prediction model is routinely
collected. It is clear as to the
basis on which referrals are made
4. UNITED pathway Biochemical, immunological and
genetic testing. Patients undergo
a series of tests: c-peptide (for
those on insulin), autoantibodies,
genetic
Treatment change offered Clear definition on which to make
referrals
5. All tested All patients diagnosed <30 years
are referred for genetic testing
Treatment change offered Will lead to increase in referrals at
the UK referral centre
NICE, National Institute for Health and Clinical Excellence; UNITED, Using genetics to Improve Treatment of Early-onset Diabetes.
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negative for these antibodies will then be offered
genetic testing for the HNF1A, HNF4A and/or GCK
mutations.
Strategy 5 is modelled as the extreme to no testing
(strategy 1) where all patients diagnosed with diabetes
under 30 years of age are referred for genetic testing.
An important distinction between patients diagnosed
with diabetes is the treatment they are currently receiv-
ing: patients not currently receiving insulin will have
demonstrated their ability to produce insulin and there-
fore do not have type 1 diabetes. In the economic evalu-
ation, the possibility of different strategies being the
most cost-effective screening strategy, depending on
current treatment, will be assessed (see table 2 for the
25 different strategies deﬁned by current treatment) in
addition to the ﬁve strategies not distinguishing indivi-
duals by treatment (the 5 shaded strategies in table 2).
Defining model structure
To allow modelling of the short-term test–treatment
events as well as their long-term consequences, a hybrid
decision model will be used consisting of a decision tree
(in MicroSoft Excel 2007) to model the short-term costs
and beneﬁts which will inform parameters in an estab-
lished, long-term diabetes model.
Decision tree
Simpliﬁed versions of decision trees for test–treatment
strategies 2–5 are shown in ﬁgures 1 and 2. Strategy 1 is
not shown due to its simplicity: no testing or treatment
change for anyone.
Genetic testing
Genetic testing is undertaken in strategies (2–5). A model-
ling assumption is that if a mutation is suspected in the
HNF1A or HNF4A genes, both will be tested simultan-
eously. This is based on the current system at the UK refer-
ral centre for monogenic diabetes, the Royal Devon and
Exeter NHS Foundation Trust (RDEFT), which allows sim-
ultaneous testing of HNF1A and HNF4A genes at a
reduced cost. Assessment of clinical criteria for deciding
whether the HNF1A and HNF4A gene mutations or the
GCK gene mutation is initially tested is based on the judge-
ment of experts in monogenic diabetes. These clinical cri-
teria include patient age at diagnosis, BMI, any evidence
of sensitivity to sulfonylureas, family history, HbA1c and
fasting blood glucose among others.27 It is assumed that
all positive genetic tests are correct, that is, that there are
no false-positive genetic test results, and any negative tests
are correct, that is, there are no false-negative test results.
Data on the decision as to whether a sample is initially
tested for the HNF1A and HNF4A gene mutations or
the GCK mutation are available from the current data-
base of referrals to the UK referral centre.
UCPCR test
The UCPCR test is part of the UNITED strategy
(strategy 4). This test is only offered to those in the mod-
elled cohort currently receiving insulin treatment.
Table 2 The 25 strategies to be evaluated in the
proposed decision model
UNITED, Using genetics to Improve Treatment of Early-onset
Diabetes.
Figure 1 Simplified decision tree for strategy 2 (current practice), strategy 3 (clinical prediction model) and strategy 5 (all tested).
4 Peters JL, Anderson R, Hyde C. BMJ Open 2013;3:e002905. doi:10.1136/bmjopen-2013-002905
Development of an economic evaluation of diagnostic strategies
 group.bmj.com on June 7, 2013 - Published by bmjopen.bmj.comDownloaded from 
Patients testing positive for the UCPCR test are assumed
to be producing their own insulin.
Thresholds for the UCPCR test that discriminates
patients who are producing their own insulin from
patients who are not have been identiﬁed for adults12
and children (unpublished data). In adults with a diag-
nosis of diabetes of ≥5 years, a threshold of 0.2 nmol/
mmol has 97% sensitivity and 96% speciﬁcity for dis-
criminating patients with mutations in HNF1A or
HNF4A genes from those with type 1 diabetes.12
The optimum UCPCR thresholds for clinical practice
may not necessarily be the optimum thresholds for cost-
effectiveness. Therefore, in sensitivity analyses, the
impact of assuming different UCPCR thresholds for dis-
criminating monogenic diabetes from type 1 diabetes
will be assessed on the estimates of cost-effectiveness.
Pancreatic autoantibody tests
Pancreatic autoantibody tests are also part of the
UNITED strategy (strategy 4) to distinguish patients with
monogenic diabetes from those with type 1 diabetes in
the honeymoon phase. All patients testing positive for
UCPCR and those patients who currently receive non-
insulin treatment are offered the tests. As in practice,
the two antibodies (GAD and IA-2) are tested simultan-
eously. If patients test negative for either of these anti-
bodies, they are offered the genetic test.
Recent data are available on the ability of pancreatic
autoantibody tests to discriminate between patients with
mutations in GCK, HNF1A or HNF4A genes and those
with type 1 diabetes.13 A negative GAD test had a sensi-
tivity of 99% and a speciﬁcity of 62%, while a negative
IA-2 test has a sensitivity of 100% and a speciﬁcity of
57%. However, by combining these tests so that a
negative result from the GAD or the IA-2 test is deﬁned
as a negative result, greater discriminatory power is
achieved: 99% sensitivity and 82% speciﬁcity.
Uptake and repeat tests
The uptake of testing may not be 100% in the screening
strategies due to the fact that urine and blood samples
are required and the decision tree will allow for this.
The model also allows for the possibility that some
patients will be asked to provide more than one (urine
or blood) sample for the C-peptide and autoantibody
tests. Repeat tests (UCPCR, pancreatic autoantibody
or genetic) on the same sample may also be required
for some patients and these will be incorporated
into the model.
For strategies 2, 3 and 5, it will be difﬁcult to estimate
the proportion of patients refusing referrals for genetic
testing as these data do not exist. However, for strategy 4,
data from the UNITED study will inform the uptake of
genetic testing, as well as the uptake of the C-peptide
and autoantibody tests. Estimates of uptake from the
UNITED study will be used to inform the uptake of
genetic testing in strategies 2, 3 and 5. Similarly, data on
the proportion of additional urine and blood samples
required from patients for repeat tests in strategy 4, and
the number of repeat tests carried out, available from
the UNITED study, will be used to inform estimates for
strategies 2, 3 and 5.
Treatment
For all strategies involving a treatment change, only
patients having a genetically conﬁrmed diagnosis of
monogenic diabetes due to mutations in the GCK,
HNF1A and HNF4A genes will be offered a change in
Figure 2 Simplified decision tree for strategy 4 (Using genetics to Improve Treatment of Early-onset Diabetes pathway).
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treatment. Patients with the GCK mutation currently
receiving treatment will be offered dietary advice so that
they can stop treatment, whereas patients with the
HNF1A or HNF4A mutation will be offered treatment
transfer to sulfonylureas. Some patients may not cease
insulin treatment, but with the addition of sulfonylureas,
their insulin dose may be reduced.5 Data from the
UNITED study will be used to inform this aspect of the
model. The impact of any non-compliance of the
current or new treatment will be modelled, as will any
treatment-related adverse events, for example, mild
hypoglycaemia when transferring from insulin to sulfo-
nylureas.5 There may also be an increase in home blood
glucose monitoring during treatment transfer. The
model will allow for the possibility that some patients
may refuse or fail treatment transfer. If patients do not
have a test for monogenic diabetes or have a negative
genetic test result, it is assumed that they will continue
on their current treatment.
Time horizon
The decision tree time horizon will be long enough to
capture all costs and health-related outcomes up until
12 months after patients with monogenic diabetes have
attempted treatment transfer onto sulfonylureas or diet,
as appropriate. The UNITED strategy has the longest
time delay before patients attempt treatment change,
and so, based on this strategy, the time horizon for the
decision tree will be 16 months in the base case analyses.
Long-term diabetes model
A total of 11 diabetes models, described in Yi et al21 and/or
Tarride et al,22 were reviewed. They were the IMS CDM,28
UKPDS,29 Archimedes,30 EAGLE,31 DCCT,32 DMM,33
Eastman,34 35 GDM,36 JADE,37 DiDACT38 and CDC39
models. The results from applying the assessment criteria
deﬁned in the ‘Deﬁning model structure’ section to these
11 models are given in web appendix 1. For some of the
diabetes models, not enough evidence could be found to
evaluate all the criteria. However, a number of diabetes
models met all or many of the criteria including the IMS
CDM,28 the UKPDS model,29 the Archimedes model30 and
the Eagle model.31 We identiﬁed the IMS CDM in particu-
lar as it corresponds to the ADA modelling criteria, was
well received at the fourth Mount Hood challenge,40 has
been used in NICE HTAs41 as well as in HTAs world-
wide42 43 and has been developed over a period of 12 years.
Details on the IMS CDM have been described and sum-
marised in a number of published articles (eg, Palmer
et al,28 Yi et al21 and Tarride et al22). It uses 15 Markov sub-
models to simulate outcomes and costs for type 1 and
type 2 diabetes patient cohorts, covering a range of
macrovascular, microvascular and treatment-related com-
plications with interaction between the submodels.28
Baseline patient characteristics contribute to the calcula-
tion of the clinical outcomes and their costs, as do the
risk factors such as age, duration of diabetes, HbA1c,
body mass index (BMI) and treatment.
Data on HbA1c, age, weight, sex, duration of diabetes
and current treatment, informed by the UNITED study,
as well as the total costs and health outcomes from the
short-term decision tree model will feed into the long-
term diabetes model, so that total costs and outcomes
can be calculated for each strategy.
Study population
The economic evaluation will consider all patients
under the age of 30 years who are diagnosed with dia-
betes, regardless of whether they are insulin-treated or
not. The cut-off of 30 years is based on evidence indicat-
ing that patients with monogenic diabetes are generally
diagnosed with diabetes by this age, but usually misdiag-
nosed with type 1 diabetes.44 45 The cost-effectiveness of
different test–treatment strategies will be evaluated in a
prevalent cohort of patients, as well as in a mixture of
prevalent and future incident cohorts to evaluate the
cost-effectiveness of strategies should they be rolled out
on a permanent basis.45
Disease progression
Data relevant to the long-term outcomes of patients with
the HNF1A mutation are available from two papers:
Steele et al 201046 and Isomaa et al 1998.47 Steele et al46
report on the risk of mortality (cardiovascular and all
cause) in HNF1A patients compared to non-diabetic
family members in the UK from a retrospective analysis.
Isomaa et al47 report the prevalence of diabetic compli-
cations in HNF1A, type 1 and type 2 patients in Finland
in a cross-sectional study. Both these studies are limited
by the study design (Isomaa et al is cross-sectional, Steele
et al is retrospective). However, as the identiﬁcation of
monogenic diabetes is relatively new, there are less long-
term data available, which will therefore be subject to
greater uncertainty than for type 1 or type 2 diabetes.
Health-state utility values
For base case analyses, utility values will be deﬁned
using the EQ-5D where possible, in line with NICE’s pre-
ferred method.48 EQ-5D data are being collected in the
UNITED study and will inform the short-term decision
model. Utility values, those from the EQ-5D for a UK
population, if available, will be sought from the litera-
ture for the long-term model.
Resource use and costs
Patterns of resource use by patients will differ by screen-
ing strategy. The hybrid model will include:
▸ Patient visits to healthcare professionals including
GPs, diabetes nurses and consultant diabetologists for
▸ Monitoring
▸ Transfer in treatment
▸ Diabetic nurse time outside of patient visits (eg, tele-
phone calls, especially likely when transferring
treatment)
▸ Home blood glucose monitoring strips
▸ Inpatient stays
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▸ Accident and emergency visits (eg, for major hypogly-
caemic events)
▸ Long-term care (eg, retinopathy screening)
For some of the strategies, there will be a one-off cost
associated with implementation of the strategy itself, as
well as likely ongoing costs for maintenance or training.
Treatment costs will include the cost of drug acquisi-
tion, taken from the most recent BNF (currently
BNF6449), as well as any drug administration costs.
There will also be a one-off cost for dietary advice for
patients transferring off all treatment. In addition to the
treatment costs, the model will include treatment trans-
fer costs, for example, the costs for diabetes nurse time
for monitoring of patients during transfer of treatment
as estimated from the UNITED study.
A major cost component will be the costs of diabetes-
related complications experienced during a patient’s
lifetime. These cost estimates will be based on the most
recent NHS Reference costs (currently50) and data from
the literature.
Outcomes
The primary outcome will be the cost per QALY gained
associated with each test–treatment strategy in compari-
son with the other strategies. An incremental analysis will
be undertaken as all strategies to be modelled are realistic
alternatives to each other. Secondary outcomes will
include the cost per life-year gained, the cost per case
identiﬁed and the cost per successful treatment transfer.
Base case perspective, discounting and time horizon
As preferred by NICE, the perspective of the model will
be that of the NHS and Personal Social Services (PSS),
with all costs and outcomes after the ﬁrst year dis-
counted at an annual rate of 3.5%.48 A lifetime horizon
is modelled.
Internal validation
The decision model will undergo thorough testing and
debugging by the model developer, and will be checked
by a second experienced decision modeller. Internal val-
idation of the decision model will be undertaken using
data from the UNITED study.
DISCUSSION
In this paper, we have described the design and develop-
ment of a new model for evaluating the long-term clin-
ical effectiveness and cost-effectiveness of test–treatment
strategies for patients with monogenic diabetes. Using
critical appraisal methods and explicit expert input, the
test–treatment strategies and model structure have been
deﬁned. Deﬁning a model structure for any economic
evaluation requires decisions to be made. However, the
results of decision models are highly dependent on the
range of comparators used, the decisions and assump-
tions regarding model structure as well as the evidence
to inform parameters.15 Thus, explicit deﬁnition of the
model with expert input and critical appraisal of existing
models provides a justiﬁable model structure, lending
credibility to the decision model and the subsequent
cost-effectiveness results.
Although much of the model structure has been
informed either by literature or experts, arbitrary
choices have still been made. For instance, the time
horizon of the short-term decision model is 16 months,
based on the UNITED pathway: 4 months from initial
test to treatment change plus 12-month treatment
change follow-up. This is based on the length of the
UNITED study, with the 12-month follow-up data used
to predict long-term events in the IMS CDM. It is not
clear whether outcomes at 12-month follow-up are the
best data to predict long-term events in the IMS CDM.
However, decision modelling allows investigation of the
impact of such choices through sensitivity analysis.
More important is the validity of the model—that is,
its ability to accurately predict the outcome or other
relevant data on which the model was not originally
based. As there are less data on monogenic diabetes, all
available data on the test–treatment strategies and care
pathways have or will be used to inform and/or param-
eterise the short-term model. Thus, there are no data
available to allow external validation of the short-term
model. Similarly, although the IMS CDM has undergone
internal and external validation for type 1 and type 2
cohorts of patients, there has been no validation of this
model, or any diabetes model, for monogenic diabetes.
This further highlights the importance of face validity of
the model, including the strategies to be evaluated and
the model structure.
The next steps in developing the decision model are:
(1) to validate the short-term decision tree model when
relevant data from the UNITED study are available and
(2) to identify relevant and most up-to-date data to
populate the decision model.
CONCLUSIONS
Economic evaluation of test–treatment strategies in
monogenic diabetes is difﬁcult because of the possible
number of realistic test–treatment strategies and asso-
ciated care pathways. However, it is important to deﬁne
realistic alternative strategies and to have an informed
and defensible model structure as this is likely to impact
on the cost-effectiveness. This paper demonstrated the
feasibility of the explicit use of critical appraisal methods
and expert consultation approaches for deﬁning the
strategies and model structure, and similar methods can
be used by modellers in other conditions for developing
decision models.
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